Plain-English translation of NCT06379360 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether azacitidine or decitabine — medications that work by changing how cancer cells grow — can help keep early-stage acute myeloid leukemia in remission longer after chemotherapy. All patients in this study will receive this medication as a 'maintenance' or continuation treatment after they've already completed their initial chemotherapy and are cancer-free or have very few cancer cells remaining.
After chemotherapy, patients with early-stage acute myeloid leukemia often go into remission, but the cancer can sometimes come back. Researchers believe that giving this medication for longer — beyond just the initial chemotherapy — might help prevent that relapse and improve survival.
You likely qualify if…
You likely don't qualify if…
If you qualify for this study, you will receive maintenance medication — either azacitidine or decitabine — to help prevent your cancer from returning. You will visit the hospital or clinic regularly for your medication doses and blood tests to monitor how you are responding and how well you are tolerating the treatment. The study involves patients from multiple medical centers, and you'll continue this maintenance approach for as long as the medication is helping and you're tolerating it well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Soochow University
Enrollment target
~77 participants
Started
November 2020
Primary completion
December 2026
Age range
16 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sheng-Li Xue, M.D.
The First Affliated Hospital of Soochow University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.